Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients

Autor: Joseph L. Kuti, Curtis L. Smith, Christopher C Cooper, Gary E. Stein, Amy Scharmen, Daniel H. Havlichek, Subhashis Mitra, James M Kidd, David P. Nicolau

Publikováno v: Surgical Infections. 20:55-61

The pharmacokinetics, especially the volume of distribution (Vd), of ß-lactam antibiotics can be altered in critically ill patients. This can lead to decreased serum concentrations and a reduction in clinical cures. Ceftazidime/avibactam (CZA) is a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86bc28408f578ee87300590271d63180
https://doi.org/10.1089/sur.2018.141

Long-Acting Lipoglycopeptides for the Treatment of Bone and Joint Infections

Autor: Ahmed Abubaker, Subhashis Mitra, Christopher C Cooper, Daniel H. Havlichek, Gary E. Stein

Publikováno v: Surgical infections. 22(8)

Background: The long-acting lipoglycopeptides dalbavancin and oritavancin possess excellent microbiologic activity against gram-positive bacteria and provide prolonged tissue exposure at sites of infection. Moreover, these antibiotics are well tolera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e80a1a9239dfd81af05084e4d1dba339
https://pubmed.ncbi.nlm.nih.gov/33835882

2075. The Hypothetical Impact of Accelerate Pheno on Time to Appropriate Therapy (TTAT) and Time to Optimal Therapy (TTOT) in an Institution with an Established Antimicrobial Stewardship Program and Rapid Genotypic Organism/Resistance Marker Identification

Autor: Christopher C Cooper, Kathryn Deeds, Jason M. Pogue, Jinit Patel, Oryan Henig, Zara Hussain, Noman Hussain, Paul Lephart, Keith S Kaye, Umar Hayat, Hossein Salimnia

Publikováno v: Open Forum Infectious Diseases

Background Rapid organism identification (ID) and antimicrobial susceptibility testing (AST) can improve time to adequate therapy (TTAT) and optimal (TTOT). The Accelerate Pheno™ system (ACC) can provide ID and AST results within 7 hours. The objec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f87eb0611085a354c4c58acb24bf75e
https://doi.org/10.1093/ofid/ofy210.1731

Multicast communication on the Unison network

Autor: David H. Shrimpton, Christopher C. Cooper

Publikováno v: Computer Communications. 13:460-468

A multicast access architecture for a multiservice network is described. The system is based on the use of a distributed set of multicast agents which are responsible for regulating access to the service and for effecting the distribution of data. A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b39c376bff121763a18aab29b83bd01c
https://doi.org/10.1016/0140-3664(90)90129-5

Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept.

Autor: Alb M; Medizinische Klinik und Poliklinik II, Lehrstuhl für Zelluläre Immuntherapie, Universitätsklinikum Würzburg, Würzburg, Germany., Reiche K; Fraunhofer-Institut für Zelltherapie und Immunologie IZI, Leipzig, Germany., Rade M; Fraunhofer-Institut für Zelltherapie und Immunologie IZI, Leipzig, Germany., Sewald K; Fraunhofer-Institut für Toxikologie und Experimentelle Medizin ITEM, Hannover, Germany., Loskill P; Institute for Biomedical Engineering, Eberhard Karls University Tübingen, Tübingen, Germany.; 3R-Center for In vitro Models and Alternatives to Animal Testing, Eberhard Karls University Tübingen, Tübingen.; NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany., Cipriano M; Institute for Biomedical Engineering, Eberhard Karls University Tübingen, Tübingen, Germany.; 3R-Center for In vitro Models and Alternatives to Animal Testing, Eberhard Karls University Tübingen, Tübingen., Maulana TI; Institute for Biomedical Engineering, Eberhard Karls University Tübingen, Tübingen, Germany.; 3R-Center for In vitro Models and Alternatives to Animal Testing, Eberhard Karls University Tübingen, Tübingen., van der Meer AD; Applied Stem Cell Technologies, University of Twente, Enschede, the Netherlands., Weener HJ; Applied Stem Cell Technologies, University of Twente, Enschede, the Netherlands., Clerbaux LA; European Commission, Joint Research Centre (JRC), Ispra, Italy., Fogal B; Department on Nonclinical Drug Safety, Boehringer Ingelheim Pharmaceutical, Inc, Ridgefield, CT, USA., Patel N; Preclinical Safety, Research and Development, Sanofi-Aventis US, LLC, Cambridge, MA, USA., Adkins K; Preclinical Safety, Research and Development, Sanofi-Aventis US, LLC, Cambridge, MA, USA., Lund E; Labcorp Drug Development Inc, Derbyshire, UK., Perkins E; Labcorp Drug Development Inc, Derbyshire, UK., Cooper C; Labcorp Drug Development Inc, Derbyshire, UK., van den Brulle J; T-CURX GmbH, Würzburg, Germany., Morgan H; Novartis Biomedical Research, Novartis Campus, Basel, Switzerland., Rubic-Schneider T; Novartis Biomedical Research, Novartis Campus, Basel, Switzerland., Ling H; Novartis Biomedical Research, Cambridge, MA, USA., DiPetrillo K; Novartis Biomedical Research, Cambridge, MA, USA., Moggs J; Novartis Biomedical Research, Novartis Campus, Basel, Switzerland., Köhl U; Fraunhofer-Institut für Zelltherapie und Immunologie IZI, Leipzig, Germany., Hudecek M; Medizinische Klinik und Poliklinik II, Lehrstuhl für Zelluläre Immuntherapie, Universitätsklinikum Würzburg, Würzburg, Germany.; Fraunhofer-Institut für Zelltherapie und Immunologie IZI, Leipzig, Germany.

Publikováno v: Journal of immunotoxicology [J Immunotoxicol] 2024 Oct; Vol. 21 (sup1), pp. S13-S28. Date of Electronic Publication: 2024 Dec 10.